Acumen Pharmaceuticals, Inc., headquartered in Newton, Mass., disclosed its financial results for Q2 2026, showcasing progress in developing therapeutics to combat Alzheimer’s disease. The Company, trading on NASDAQ as ABOS, specializes in targeting toxic soluble amyloid beta oligomers (AβOs). As a clinical-stage biopharmaceutical establishment, Acumen aims to address the root cause of AD through innovative treatments. The recent business update detailed their advancements in the sector.
